July 19, 2016 TORONTO – iTP Biomedica Corp., a developer of proprietary whole transcriptome-based cancer diagnostics, today announced the launch of BladderPredict, a groundbreaking next-generation sequencing-based test that will for the first time assist uro-pathologists in assigning disease grade in early stage bladder cancer, and urologists and uro-oncologists in managing the disease. The test will be provided in collaboration with iTP’s partner, Mount Sinai Services of Toronto, a global provider of customized clinical laboratory and research services.
For the full press release, click here